生物技术通讯
生物技術通訊
생물기술통신
LETTERS IN BIOTECHNOLOGY
2014年
4期
569-573
,共5页
肿瘤%整合素αvβ3%RGD序列%诊断试剂%脂质体%胶束%纳米粒
腫瘤%整閤素αvβ3%RGD序列%診斷試劑%脂質體%膠束%納米粒
종류%정합소αvβ3%RGD서렬%진단시제%지질체%효속%납미립
tumor%integrin αvβ3%RGD%diagnostics%liposome%micelle%nanoparticle
整合素αvβ3在肿瘤细胞及肿瘤血管内皮细胞中高表达，RGD序列作为其配体，可与其进行特异性结合，为肿瘤的诊断和靶向治疗提供了理论基础。RGD诊断试剂的前期研究和临床试验数据表明其具有良好的肿瘤组织靶向性。RGD-纳米抗肿瘤制剂（RGD-脂质体、RGD-胶束和RGD-纳米粒）在体外可提高细胞对药物的吸收率，增强细胞毒性；在动物移植瘤模型中，能更好地抑制肿瘤的生长，延长了动物的生存时间。在肿瘤发病率居高不下，治疗手段和疗效都较为有限的今天，RGD靶向制剂在肿瘤诊断和治疗中所具有的优势值得特别关注。
整閤素αvβ3在腫瘤細胞及腫瘤血管內皮細胞中高錶達，RGD序列作為其配體，可與其進行特異性結閤，為腫瘤的診斷和靶嚮治療提供瞭理論基礎。RGD診斷試劑的前期研究和臨床試驗數據錶明其具有良好的腫瘤組織靶嚮性。RGD-納米抗腫瘤製劑（RGD-脂質體、RGD-膠束和RGD-納米粒）在體外可提高細胞對藥物的吸收率，增彊細胞毒性；在動物移植瘤模型中，能更好地抑製腫瘤的生長，延長瞭動物的生存時間。在腫瘤髮病率居高不下，治療手段和療效都較為有限的今天，RGD靶嚮製劑在腫瘤診斷和治療中所具有的優勢值得特彆關註。
정합소αvβ3재종류세포급종류혈관내피세포중고표체，RGD서렬작위기배체，가여기진행특이성결합，위종류적진단화파향치료제공료이론기출。RGD진단시제적전기연구화림상시험수거표명기구유량호적종류조직파향성。RGD-납미항종류제제（RGD-지질체、RGD-효속화RGD-납미립）재체외가제고세포대약물적흡수솔，증강세포독성；재동물이식류모형중，능경호지억제종류적생장，연장료동물적생존시간。재종류발병솔거고불하，치료수단화료효도교위유한적금천，RGD파향제제재종류진단화치료중소구유적우세치득특별관주。
As RGD can specifically bind to integrin αvβ3, which is up-regulated in both tumor and tumor-en-dothelial cells, this enables the targeting of diagnostics and therapeutics of tumor using the affinity between RGD and its receptor. Previous studies and data from clinical trials demonstrated RGD imaging agents can target tumor tissues. RGD-nano antitumor agents(RGD-liposome, RGD-micelle, RGD-nanoparticle) have greater cellular uptake and higher cytotoxic in vitro, make more effective in tumor growth inhibition and prolong survival times in xeno-graft models. Tumor incidence increases year by year, but therapeutics and efficacy are still very limited. The ad-vantage of RGD-peptidomimetic agents in targeting of diagnostics and therapeutics deserve special attention.
